Lot D.
- Country
- The Netherlands
- Department
- Oncology
Research Overview
- Evaluation of Petosemtamab Monotherapy and Combination Therapy in Advanced Metastatic Colorectal Cancer and Malignant Solid Tumors
- Evaluation of Petosemtamab Versus Investigator's Choice Monotherapy in Previously Treated Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma
- Phase 3 Randomized Study of Petosemtamab and Pembrolizumab in First-Line Treatment of Recurrent/Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma
Data & Insights
Has run more than one trial at 63 of 105 partner sites.
Specializations
Head and Neck Cancer
The investigator specializes in treating advanced forms of head and neck squamous cell carcinoma (HNSCC), with particular attention to both first-line and subsequent treatment approaches for patients with metastatic or recurrent conditions.
- Recurrent HNSCC Management
- Metastatic Disease Treatment
- PD-L1 Positive Cancers
Their research encompasses innovative therapeutic combinations including immunotherapy approaches for treating head and neck cancers.
Skin Cancer
The investigator focuses on developing treatments for cutaneous squamous cell carcinoma, exploring alternatives to conventional surgical and radiotherapy interventions.
- Organ Preservation Strategies
- Immunotherapy Applications
- Non-surgical Treatment Approaches
Their work aims to advance treatment options that reduce surgical morbidity while maintaining therapeutic efficacy.
Immunotherapy Innovation
The investigator explores novel immunotherapeutic approaches across multiple cancer types, with emphasis on developing less invasive treatment alternatives.
- Combination Therapy Development
- Treatment Response Assessment
- Long-term Disease Management
Their research encompasses evaluation of therapeutic responses and survival outcomes in advanced cancer cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.